An Increase in Group B Invasive Meningococcal Disease Among Adolescents and Young Adults in England Following Easing of COVID-19 Containment Measures

11 Pages Posted: 8 Jan 2022

See all articles by Stephen Clark

Stephen Clark

Meningococcal Reference Unit, UK Health Security Agency

Helen Campbell

Government of the United Kingdom - Immunisation and Countermeasures Division

Anna A. Mensah

Government of the United Kingdom - Immunisation and Countermeasures Division

Aiswarya Lekshmi

UK Health Security Agency - Meningococcal Reference Unit

Andrew Walker

Meningococcal Reference Unit, UK Health Security Agency

Sonia Ribeiro

Government of the United Kingdom - Immunisation and Countermeasures Division

Lloyd Walsh

Meningococcal Reference Unit, UK Health Security Agency

Laura Willerton

Meningococcal Reference Unit, UK Health Security Agency

Xilian Bai

Meningococcal Reference Unit, UK Health Security Agency

Jay Lucidarme

Meningococcal Reference Unit, UK Health Security Agency

Mary E. Ramsay

Public Health England - Immunisation, Hepatitis, and Blood Safety Department

Shamez Ladhani

Public Health England - Immunisation and Countermeasures Division; University of London, St. George's, Paediatric Infectious Diseases Research Group

Ray Borrow

Government of the United Kingdom - Public Health England

Date Written: December 16, 2021

Abstract

In July 2021 COVID-19 containment measures were withdrawn in England. Between September and November 2021, IMD cases increased with group B disease in adolescents/young adults rising sharply and exceeding pre-pandemic levels. The serogroup and age distribution of these cases suggests that meningococcal vaccination programmes are maintaining low rates of group C/W/Y disease however low immunity against group B strains and high transmission of meningococci among adolescents/young adults resulted in the return of group B disease, particularly in university students.

Note:
Funding: Invasive meningococcal disease surveillance in England in funded and performed by the UK Health Security Agency.

Declaration of Interests: UK Health Security Agency (UKHSA) Immunisation and Countermeasures Division has provided vaccine manufacturers with post-marketing surveillance reports which the Marketing Authorisation Holders are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. SL performs contract work on behalf of St George’s University of London for GlaxoSmithKline, Pfizer, and Sanofi Pasteur. SAC, AL, LW, XB, JL and RB perform contract research on behalf of the UKHSA for GlaxoSmithKline, Pfizer, and Sanofi Pasteur.

Ethics Approval Statement: UKHSA has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002, to process patient confidential information for national surveillance of communicable diseases and as such, individual patient consent is not required to access records.

Keywords: meningococcal, COVID-19,

Suggested Citation

Clark, Stephen and Campbell, Helen and Mensah, Anna A. and Lekshmi, Aiswarya and Walker, Andrew and Ribeiro, Sonia and Walsh, Lloyd and Willerton, Laura and Bai, Xilian and Lucidarme, Jay and Ramsay, Mary E. and Ladhani, Shamez and Borrow, Ray, An Increase in Group B Invasive Meningococcal Disease Among Adolescents and Young Adults in England Following Easing of COVID-19 Containment Measures (December 16, 2021). Available at SSRN: https://ssrn.com/abstract=3998164 or http://dx.doi.org/10.2139/ssrn.3998164

Stephen Clark (Contact Author)

Meningococcal Reference Unit, UK Health Security Agency

Clinical Sciences Building II,
Manchester Royal Infirmary
Manchester, M13 9WL
United Kingdom

Helen Campbell

Government of the United Kingdom - Immunisation and Countermeasures Division ( email )

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Anna A. Mensah

Government of the United Kingdom - Immunisation and Countermeasures Division ( email )

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Aiswarya Lekshmi

UK Health Security Agency - Meningococcal Reference Unit ( email )

London
United Kingdom

Andrew Walker

Meningococcal Reference Unit, UK Health Security Agency ( email )

Clinical Sciences Building II,
Manchester Royal Infirmary
Manchester, M13 9WL
United Kingdom

Sonia Ribeiro

Government of the United Kingdom - Immunisation and Countermeasures Division

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Lloyd Walsh

Meningococcal Reference Unit, UK Health Security Agency ( email )

Clinical Sciences Building II,
Manchester Royal Infirmary
Manchester, M13 9WL
United Kingdom

Laura Willerton

Meningococcal Reference Unit, UK Health Security Agency ( email )

Clinical Sciences Building II,
Manchester Royal Infirmary
Manchester, M13 9WL
United Kingdom

Xilian Bai

Meningococcal Reference Unit, UK Health Security Agency ( email )

Clinical Sciences Building II,
Manchester Royal Infirmary
Manchester, M13 9WL
United Kingdom

Jay Lucidarme

Meningococcal Reference Unit, UK Health Security Agency ( email )

Clinical Sciences Building II,
Manchester Royal Infirmary
Manchester, M13 9WL
United Kingdom

Mary E. Ramsay

Public Health England - Immunisation, Hepatitis, and Blood Safety Department ( email )

United Kingdom

Shamez Ladhani

Public Health England - Immunisation and Countermeasures Division ( email )

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

University of London, St. George's, Paediatric Infectious Diseases Research Group

United Kingdom

Ray Borrow

Government of the United Kingdom - Public Health England

Wellington House
133-155 Waterloo Road
London, SE1 8UG
United Kingdom

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
722
Abstract Views
3,928
rank
52,594
PlumX Metrics